Golbarg Piryaiee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Golbarg Piryaiee has a total of 2 co-authors. Here are the top co-authors by number of shared publications:
- Amirreza Veisi
Ophthalmic Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, Tehran, Iran
1 shared publication - Mohammadreza Tahavvori
Shahid Beheshti University of Medical Sciences
1 shared publication
Latest Publications
- Open Access
- 16 February 2024
- Published by Springer Nature in Research Square
Zoledronic Acid-Induced Orbital Inflammatory Disease
Bisphosphonates are a group of drugs that are used to prevent the loss of bone density and treat osteoporosis and similar bone diseases. Zoledronate (zolenedronic acid) has been increasingly used because of its advantages of intravenous infusion and annual regimens. Here, we present a case of zolendronic acid-related diffuse orbital inflammation. A 67-year-old woman with a history of breast cancer and chemotherapy developed severe unilateral orbital and periorbital swelling approximately 8 hours after receiving her first zoledronate infusion. In this case, the interval between infusion and the beginning of the symptoms was too short compared with most other reported similar cases. Her signs and symptoms relapsed 4 days after discontinuation of the short course of systemic steroid therapy. Orbital inflammation improved after systemic corticosteroid therapy was restarted, but the patient did not relapse following discontinuation of the drug in a tapering manner.
- 16 February 2024
- Published by Springer Nature in Research Square
Open AccessZoledronic Acid-Induced Orbital Inflammatory Disease
Bisphosphonates are a group of drugs that are used to prevent the loss of bone density and treat osteoporosis and similar bone diseases. Zoledronate (zolenedronic acid) has been increasingly used because of its advantages of intravenous infusion and annual regimens. Here, we present a case of zolendronic acid-related diffuse orbital inflammation. A 67-year-old woman with a history of breast cancer and chemotherapy developed severe unilateral orbital and periorbital swelling approximately 8 hours after receiving her first zoledronate infusion. In this case, the interval between infusion and the beginning of the symptoms was too short compared with most other reported similar cases. Her signs and symptoms relapsed 4 days after discontinuation of the short course of systemic steroid therapy. Orbital inflammation improved after systemic corticosteroid therapy was restarted, but the patient did not relapse following discontinuation of the drug in a tapering manner.